Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Plos One
|
November 13, 2015
Outcome-Driven Cluster Analysis with Application to Microarray Data
Jessie J Hsu, Dianne M Finkelstein, David A Schoenfeld
Communications in Statistics. Case Studies, Data Analysis and Applications
|
March 12, 2019
Informatively clustering longitudinal microarrays using binary or survival outcome data
Jessie J Hsu, Dianne M Finkelstein, David A Schoenfeld
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C Pavlick, et al.
The Oncologist
|
February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Journal of Translational Medicine
|
June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
The American Journal of Surgical Pathology
|
February 2, 2010
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma
Matija Snuderl, Olga K Kolman, Yi-Bin Chen, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Plos One
|
November 13, 2015
Outcome-Driven Cluster Analysis with Application to Microarray Data
Jessie J Hsu, Dianne M Finkelstein, David A Schoenfeld
Communications in Statistics. Case Studies, Data Analysis and Applications
|
March 12, 2019
Informatively clustering longitudinal microarrays using binary or survival outcome data
Jessie J Hsu, Dianne M Finkelstein, David A Schoenfeld
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 2019
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma
Antoni Ribas, Adil Daud, Anna C Pavlick, et al.
The Oncologist
|
February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Journal of Translational Medicine
|
June 26, 2017
Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study
Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
The American Journal of Surgical Pathology
|
February 2, 2010
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma
Matija Snuderl, Olga K Kolman, Yi-Bin Chen, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
Page
of 1